This page lists current opportunities from CIP.
The NCI's Division of Extramural Activities provides information about newly approved concepts, which may become RFAs and PAs. Check the Concepts Cleared at the NCI Board of Scientific Advisors Meeting web site for the earliest possible information about future initiatives.
Source: FOA page
This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.
Source: FOA Page
Huiming Zhang, Ph.D., NCI, Phone: 240-276-5979, (email@example.com)
Cheryl L. Marks, Ph.D., NCI, Phone: 240-276-6217 (firstname.lastname@example.org)
Richard V. Mazurchuk, Ph.D., NCI, Phone: 240-276-7126 (email@example.com)
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve correlation of results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations.
Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients’ malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, , imaging platforms, QI methods, decision support software and informatics to populate the research resource.
Source: FOA Page
Houston Baker, Ph.D., NCI. Phone: 240-276-5908 (firstname.lastname@example.org)
Miguel Ossandon, M.S., NCI. Phone: 240-276-5714 (email@example.com)
Rao L. Divi, Ph.D., NCI. Phone: 240-276-6913 (firstname.lastname@example.org)
Tiffani Bailey Lash, Ph.D., NIBIB. Phone: 301-451-4778 (email@example.com)
This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem. The proposed systems may include molecular diagnosis, molecular imaging or related research resources. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following examples, among others: (a) current commercially supported systems, (b) next-generation systems, (c) quality assurance and quality control, (d) validation and correlation studies, (e) quantitative imaging, and (f) related research resources. Because applications should be translational in scope, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. In addition, innovation may be considered as delivery of a new capability to end users. The partnership on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their system to solve their chosen cancer problem. This FOA will support clinical trials that test functionality, optimize, and validate the performance of the proposed translational work. This FOA does not intend to support either actual commercial production or basic research projects that do not emphasize translation.